Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.42 |
| ▸ | MEN1 | O00255 | 4/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11190844 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11481324 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11182379 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11178432 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11178268 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11187787 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11185580 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11176239 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11474854 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT | |
| SCHEMBL11180830 | 0.98 | ALDH1A1 (0.41) | ALDH1A1LMNAKMT2AMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2063914-B1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA KS (CZ) | 2018-12-26 | — | — | EP | claimed |
| US-20120045851-A1 | LABELS, THEIR PRODUCTION PROCESS AND THEIR USES | LABORATOIRES SYNTH-INNOVE (FR) | 2012-02-23 | — | — | US | claimed |
| US-8034626-B2 | Labels, their production process and their uses | LABORATOIRES SYNTH-INNOVE (FR) | 2011-10-11 | — | — | US | claimed |
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA K.S. (CZ) | 2009-12-10 | — | — | US | claimed |
| EP-2063914-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | Zentiva, k.s. (CZ) | 2009-06-03 | — | — | EP | claimed |
| US-20080318336-A1 | Labels, Their Production Process And Their Uses | LABORATOIRES SYNTH-INNOVE (FR) | 2008-12-25 | — | — | US | claimed |
| WO-2008034391-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | ZENTIVA, A.S. (CZ) | 2008-03-27 | — | — | WO | claimed |
| EP-0218415-B1 | PROCESS FOR INTERMEDIATES TO 1-CARBAPENEMS AND 1-CARBACEPHEMS | THE UNIVERSITY OF NOTRE DAME DU LAC (US) | 1990-08-08 | — | — | EP | claimed |
| US-4745201-A | Process for intermediates to 1-carbapenems and 1-carbacephems | UNIVERSITY OF NOTRE DAME DU LAC (US) | 1988-05-17 | — | — | US | claimed |
| JP-54079201-A | — | — | None | — | — | JP | disclosed |
| JP-10017530-A | — | — | None | — | — | JP | disclosed |
| JP-7010853-A | — | — | None | — | — | JP | disclosed |
| JP-4069386-A | — | — | None | — | — | JP | disclosed |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | Blaze Bioscience, Inc. (US) | 2024-01-09 | — | — | US | disclosed |
| US-4474814-A | Radiosensitizing nitrobenzoic acid amide derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1984-10-02 | — | — | US | disclosed |
| EP-0081726-A1 | Nitrobenzoic acid amide derivatives | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1983-06-22 | — | — | EP | disclosed |
| EP-0017039-B1 | PROCESS FOR THE PREPARATION OF THIAZOLIDINE-2-THIONES | BAYER AG (DE) | 1983-01-12 | — | — | EP | disclosed |
| EP-0017039-A1 | Process for the preparation of thiazolidine-2-thiones | BAYER AG (DE) | 1980-10-15 | — | — | EP | disclosed |
| JP-S5479201-A | PREPARATION OF ALDEHYDES | MITSUBISHI CHEM IND LTD | 1979-06-25 | — | — | JP | disclosed |
| US-4148800-A | FROM AMINOETHANOLS AND THIONYL CHLORIDE AND CARBON DISULFIDE | BAYER AKTIENGESELLSCHAFT (DE) | 1979-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306004-A1 | GRAFTED MACROMOLECULAR CONJUGATES OF DOXORUBICIN WITH ANTICANCER ACTIVITY AND METHOD OF THEIR PREPARATION | DNPEP, HDGF, LNPEP | ALDH1A1 2116/4885LMNA 2049/4885KMT2A 3752/4885 |
| US-11866466-B2 | Tumor homing and cell penetrating peptide-immuno-oncology agent complexes and methods of use thereof | TAP1, CXCL12, CCL2 | ALDH1A1 4713/4885LMNA 4540/4885KMT2A 4216/4885 |
| US-20120045851-A1 | LABELS, THEIR PRODUCTION PROCESS AND THEIR USES | HLCS, PFAS, CYBA | ALDH1A1 347/4885LMNA 424/4885KMT2A 2800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.